Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$70.30

1.73 (2.52%)

, MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

16:34
10/05/16
10/05
16:34
10/05/16
16:34

Alnylam ends revusiran development after nerve damage risk

Alnylam Pharmaceuticals (ALNY) announced that, upon the recommendation of the ENDEAVOUR Phase 3 study data monitoring committee to suspend dosing, the company has decided to discontinue development of revusiran, an investigational RNA interference therapeutic that was being developed for the treatment of hereditary ATTR amyloidosis with cardiomyopathy. "This decision was made yesterday evening and has been communicated to investigators, study sites, and regulatory authorities. Following recent reports in the Phase 2 OLE study of new onset or worsening peripheral neuropathy, the ENDEAVOUR DMC assembled yesterday at the company's request to review these reports and ENDEAVOUR data on an unblinded basis. The DMC did not find conclusive evidence for a drug-related neuropathy signal in the ENDEAVOUR trial, but informed the company that the benefit-risk profile for revusiran no longer supported continued dosing. The company subsequently reviewed unblinded ENDEAVOUR data which revealed an imbalance of mortality in the revusiran arm as compared to placebo... We remain committed to serving the needs of the ATTR amyloidosis community," the company explained. The company noted it will "continue to evaluate ENDEAVOUR data to understand the potential cause of these findings." The decision to discontinue development of revusiran does not affect patisiran, which is currently in Phase 3 development for the treatment of hATTR amyloidosis with polyneuropathy, or any other Alnylam investigational RNAi therapeutic program in development. Based on a current assessment of the safety data across the company's other programs, which include the ALN-PCSsc program partnered with The Medicines Company (MDCO), there is no evidence of a drug-related neuropathy signal in over 800 treated subjects and patients with exposure of up to 34 months. The company reaffirms its "Alnylam 2020" guidance and remains committed to the advancement of these investigational RNAi therapeutics.

ALNY

Alnylam

$70.30

1.73 (2.52%)

MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

  • 14

    Oct

  • 06

    Nov

ALNY Alnylam
$70.30

1.73 (2.52%)

08/22/16
WEDB
08/22/16
NO CHANGE
WEDB
Intellia Therapeutics data positive, says Wedbush
Wedbush analyst David Nierengarten says that additional data on Intella's (NTLA) TTR program in mice was "meaningful" and indicates that the program compares favorably with competing products. The analyst says that competing programs, including those of Alnylam (ALNY) and Ionis (IONS) have shown "only a transient benefit." He reiterates a $38 price target and Outperform rating on Intella.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
09/15/16
09/15/16
INITIATION
Target $82

Underperform
FBR calls Alexion overvalued, starts shares at Underperform
FBR Capital analyst Christopher James initiated coverage of Alexion Pharmaceuticals (ALXN) with an Underperform rating and $82 price target. The biotech focused on patients with ultra-rare disorders closed yesterday up $2.63 to $129.42. Alexion shares are overpriced as the company is facing a competitive near-term landscape, particularly from Alnylam's (ALNY) ALN-CC5, James tells investors in a research note. Further, near-term expansion into additional indications will be challenging given the recent failed study with eculizumab in refractory generalized myasthenia gravis, the analyst contends. He also sees possible pricing pressures from biosimilars, including an Amgen (AMGN) biosimilar product in development. James this morning also initiated Achillion Pharmaceuticals (ACHN) and Arena Pharmaceuticals (ARNA) with Outperform ratings.
09/28/16
JANY
09/28/16
INITIATION
Target $74
JANY
Neutral
Alnylam initiated with a Neutral at Janney Capital
Janney Capital analyst Roy Buchanan initiated Alnylam with a Neutral and a $74 fair value estimate. The analyst is not confident about the outcome for the pivotal study for patisiran in transthyretin familial amyloid neuropathy, expected in about 12 months, and give patisiran a 50% chance of success.
MDCO The Medicines Co.
$38.51

0.32 (0.84%)

05/13/16
JEFF
05/13/16
NO CHANGE
Target $43
JEFF
Buy
The Medicines Co. could rally $4/share on positive data, says Jefferies
Jefferies analyst Biren Amin says The Medicines Co. has a "catalyst-rich" second half of 2016, including the Phase III trials of Carbavance in complicated urinary tract infections and carbapenem resistant enterobacteriaceae infections. The analyst expects both of the trials will be successful and show non-inferiority leading to potential FDA approval. Amin thinks shares could move $3 to $4 per share on positive data readout. He keeps a Buy rating on The Medicines Co. with a $43 price target.
07/11/16
JEFF
07/11/16
NO CHANGE
Target $43
JEFF
Buy
Jefferies views The Medicines Co. ruling as positive surprise
Jefferies analyst Biren Amin views today's Court of Appeals ruling as a "positive surprise" for The Medicines Company. The ruling "breathes potential life" into the company's Angiomax patents, Amin tells investors in a research note. He expects Hospira to file an appeal within 90 days. The analyst has a Buy rating on The Medicines Co. with a $43 price target.
08/02/16
EVER
08/02/16
NO CHANGE
EVER
Buy
Pfizer shelves oral PCSK9, a Medicines Co. competitor, says Evercore ISI
Evercore ISI analyst Umer Raffat said Pfizer (PFE) management does not thin the profile for oral PCSK9 will be competitive with the strong efficacy of antibodies and have moved other interesting products forward. Raffat said some Medicines Co. (MDCO) investors had worried that a potential oral PCSk9 from Pfizer could greatly reduce enthusiasm for an every-6-month PCSk9 from MDCO. The analyst said the next catalyst for The Medicines Co. is A1 Milano readout this month. Raffat rates The Medicines Co. a Buy with a $52 price target.

TODAY'S FREE FLY STORIES

CENT

Central Garden & Pet

$37.82

0.09 (0.24%)

20:37
01/22/18
01/22
20:37
01/22/18
20:37
Upgrade
Central Garden & Pet rating change at KeyBanc »

Central Garden & Pet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPAR

Inter Parfums

$45.90

-1.9 (-3.97%)

20:33
01/22/18
01/22
20:33
01/22/18
20:33
Downgrade
Inter Parfums rating change at KeyBanc »

Inter Parfums downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$148.14

0.78 (0.53%)

, PG

Procter & Gamble

$91.89

0.82 (0.90%)

20:25
01/22/18
01/22
20:25
01/22/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

JNJ

Johnson & Johnson

$148.14

0.78 (0.53%)

PG

Procter & Gamble

$91.89

0.82 (0.90%)

VZ

Verizon

$53.46

1.55 (2.99%)

KMB

Kimberly-Clark

$116.91

1.42 (1.23%)

TRV

Travelers

$139.35

1.5 (1.09%)

FITB

Fifth Third

$32.77

0.27 (0.83%)

HBAN

Huntington Bancshares

$16.03

0.22 (1.39%)

WAT

Waters

$214.77

4.05 (1.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 06

    Feb

  • 13

    Feb

  • 16

    Feb

  • 08

    Mar

SSNLF

Samsung

19:26
01/22/18
01/22
19:26
01/22/18
19:26
Hot Stocks
Samsung says new tariff 'great loss' for American consumers, workers »

In reaction to a final…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

FTK

Flotek

$5.71

0.07 (1.24%)

19:23
01/22/18
01/22
19:23
01/22/18
19:23
Hot Stocks
Flotek expands lines of chemistry technologies »

Flotek Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

ACLS

Axcelis

19:22
01/22/18
01/22
19:22
01/22/18
19:22
Upgrade
Axcelis rating change at Stifel »

Axcelis upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$90.64

2.8 (3.19%)

19:22
01/22/18
01/22
19:22
01/22/18
19:22
Downgrade
Wayfair rating change at Stifel »

Wayfair downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

EPE

EP Energy

$2.48

0.17 (7.36%)

19:00
01/22/18
01/22
19:00
01/22/18
19:00
Conference/Events
EP Energy to hold a conference call »

Management discusses its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

BRSS

Global Brass and Copper

$33.30

-0.55 (-1.62%)

18:47
01/22/18
01/22
18:47
01/22/18
18:47
Hot Stocks
Global Brass and Copper reports oil spill at Somers Thin Strip plant »

Somers Thin Strip, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$227.58

7.12 (3.23%)

, DIS

Disney

$111.10

0.51 (0.46%)

18:38
01/22/18
01/22
18:38
01/22/18
18:38
Hot Stocks
Netflix doesn't see Disney-Fox deal as a direct threat »

Says Disney (DIS) and Fox…

NFLX

Netflix

$227.58

7.12 (3.23%)

DIS

Disney

$111.10

0.51 (0.46%)

FOX

21st Century Fox

$36.96

0.7 (1.93%)

FOXA

21st Century Fox

$37.31

0.66 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

T

AT&T

$37.87

0.66 (1.77%)

, TWX

Time Warner

$94.00

0.64 (0.69%)

18:37
01/22/18
01/22
18:37
01/22/18
18:37
Periodicals
Judge orders DOJ to seek consent to give data to AT&T, Time Warner, Reuters says »

Judge Richard Leon, who…

T

AT&T

$37.87

0.66 (1.77%)

TWX

Time Warner

$94.00

0.64 (0.69%)

DIS

Disney

$111.10

0.51 (0.46%)

FOX

21st Century Fox

$36.96

0.7 (1.93%)

FOXA

21st Century Fox

$37.31

0.66 (1.80%)

VIA

Viacom

$39.30

0.1 (0.26%)

VIAB

Viacom

$33.94

0.58 (1.74%)

DISCA

Discovery

$26.33

0.62 (2.41%)

SNI

Scripps Networks

$88.77

0.27 (0.31%)

CMCSA

Comcast

$42.89

0.39 (0.92%)

CMCSK

Comcast

CHTR

Charter

$370.25

4.2 (1.15%)

ATUS

Altice USA

$21.90

0.6 (2.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 08

    Feb

  • 08

    Feb

  • 12

    Feb

  • 27

    Feb

NFLX

Netflix

$227.58

7.12 (3.23%)

18:25
01/22/18
01/22
18:25
01/22/18
18:25
Hot Stocks
Netflix says it has a ways to go to hit 60M U.S. subscribers »

Says has a ways to go to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

BIVV

Bioverativ

$103.79

39.68 (61.89%)

, SNY

Sanofi

$43.20

-1.4 (-3.14%)

18:15
01/22/18
01/22
18:15
01/22/18
18:15
Downgrade
Bioverativ, Sanofi rating change at Jefferies »

Bioverativ downgraded to…

BIVV

Bioverativ

$103.79

39.68 (61.89%)

SNY

Sanofi

$43.20

-1.4 (-3.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 14

    Feb

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 25

    Apr

  • 02

    May

ECR

Eclipse Resources

$2.33

0.05 (2.19%)

18:12
01/22/18
01/22
18:12
01/22/18
18:12
Conference/Events
Eclipse Resources to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$227.58

7.12 (3.23%)

18:10
01/22/18
01/22
18:10
01/22/18
18:10
Hot Stocks
Netflix says Asia market projects 'well' »

Says very pleased with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

STLD

Steel Dynamics

$46.57

0.15 (0.32%)

18:06
01/22/18
01/22
18:06
01/22/18
18:06
Hot Stocks
Steel Dynamics CEO says domestic inventory levels moderated »

Steel Dynamics CEO Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

STLD

Steel Dynamics

$46.57

0.15 (0.32%)

18:04
01/22/18
01/22
18:04
01/22/18
18:04
Earnings
Steel Dynamics reports Q4 EPS 54c excluding items, consensus 52c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

IMI

Intermolecular

$1.61

0.14 (9.52%)

18:02
01/22/18
01/22
18:02
01/22/18
18:02
Hot Stocks
Intermolecular and SITRI expand alliance to address Chinese market »

Intermolecular and SITRI…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

EXFO

EXFO Inc.

$4.35

-0.05 (-1.14%)

, CHL

China Mobile

$51.97

0.45 (0.87%)

18:01
01/22/18
01/22
18:01
01/22/18
18:01
Hot Stocks
EXFO partners with China Mobile to prepare network for IoT »

EXFO Inc. (EXFO)…

EXFO

EXFO Inc.

$4.35

-0.05 (-1.14%)

CHL

China Mobile

$51.97

0.45 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$111.12

-1.84 (-1.63%)

18:00
01/22/18
01/22
18:00
01/22/18
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

SFNC

Simmons First National

$59.50

0.35 (0.59%)

18:00
01/22/18
01/22
18:00
01/22/18
18:00
Earnings
Simmons First National reports Q4 core EPS 97c, consensus 88c »

Reports Q4 core net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

WHR

Whirlpool

$166.65

-0.88 (-0.53%)

, SSNLF

Samsung

17:59
01/22/18
01/22
17:59
01/22/18
17:59
Hot Stocks
Whirlpool chairman praises Trump's move to establish tariff on washing machines »

Whirlpool (WHR) chairman…

WHR

Whirlpool

$166.65

-0.88 (-0.53%)

SSNLF

Samsung

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 30

    Jan

AMBC

Ambac Financial

$16.02

0.07 (0.44%)

17:48
01/22/18
01/22
17:48
01/22/18
17:48
Hot Stocks
Ambac Financial announces approval of plan amendment »

Ambac Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STML

Stemline

$14.25

0.7 (5.17%)

17:47
01/22/18
01/22
17:47
01/22/18
17:47
Conference/Events
Stemline participates in a conference call with JPMorgan »

Investor conference call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

EFSC

Enterprise Financial

$47.70

-0.025 (-0.05%)

17:42
01/22/18
01/22
17:42
01/22/18
17:42
Earnings
Enterprise Financial reports Q4 EPS 77c, consensus 77c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.